Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viracept for Cutaneous and Mucosal KS in AIDS
NCT00002185Phase 2Completed
- Sponsor
- Agouron Pharmaceuticals
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nelfinavir in Kaposi sarcoma (KS) (2 arms), sponsored by Agouron Pharmaceuticals. Primary endpoint: Response to therapy at 2 months. Status: completed.
02
Drugs
nelfinavir
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00002185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002185.